EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis

Meiling Jin, Jo A Douglass, J Stuart Elborn, Ritesh Agarwal, William J Calhoun, Slawomir Lazarewicz, Xavier Jaumont, Meng Yan

The Journal of Allergy and Clinical Immunology: In Practice · 2023-03 · 11 (3) · 896-905

DOI: 10.1016/j.jaip.2022.12.012 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2023-03. Verfasst von Meiling Jin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: mljin118@163.com. Hauptthemen laut MEDLINE: Aspergillosis, Allergic Bronchopulmonary, Cystic Fibrosis, Asthma. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma AG, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: An unmet clinical need exists in the management of treatment-refractory allergic bronchopulmonary aspergillosis (ABPA). Omalizumab has shown promising effects in case series and cohort studies; however, evidence to support its routine clinical use is lacking. OBJECTIVE: The aim of this systematic review and meta-analysis was to evaluate the clinical effectiveness and safety of omalizumab in patients with ABPA. METHODS: We conducted a systematic search across standard databases using specific key words until May 13, 2021. We performed a meta-analysis to compare the effectiveness (exacerbations, oral corticosteroid [OCS] use, lung function, and patient-reported asthma control) and safety of pre- and post-omalizumab treatment. Subgroup analyses were performed for treatment duration and underlying disease. RESULTS: In total, 49 studies (n = 267) were included in the qualitative synthesis and 14 case series (n = 186) in the quantitative meta-analysis. Omalizumab treatment significantly reduced the annualized exacerbation rate compared with pretreatment (mean difference, -2.09 [95% CI, -3.07 to -1.11]; P < .01). There was a reduction in OCS use (risk difference, 0.65 [95% CI, 0.46-0.84]; P < .01), an increase in termination of OCS use (risk difference, 0.53 [95% CI, 0.24-0.82]; P < .01), and a reduction in OCS dose (milligrams per day) (mean difference, -14.62 [95% CI, -19.86 to -9.39]; P < .01) in ABPA patients receiving omalizumab. Omalizumab improved FEV1 % predicted by 11.9% (95% CI, 8.2-15.6; P < .01) and asthma control, and was well-tolerated. CONCLUSIONS: Omalizumab treatment reduced exacerbations and OCS use, improved lung function and asthma control in patients with ABPA, and was well-tolerated. The results highlight the potential role of omalizumab in the treatment of ABPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aspergillosis, Allergic BronchopulmonaryCystic FibrosisAsthmaHumansOmalizumabAdrenal Cortex Hormones

Stichwörter der Autor:innen

ACT scoreAllergic bronchopulmonary aspergillosisAsthmaCystic fibrosisExacerbationsLung functionMeta-analysisOmalizumabOral corticosteroids

Substanzen

OmalizumabAdrenal Cortex Hormones

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China. Electronic address: mljin118@163.com.
  • Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.
  • Faculty of Medicine, Health, and Life Sciences, Queen's University, Belfast, United Kingdom.
  • Department of Pulmonary Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas.
  • Novartis Pharma AG, Basel, Switzerland.

Förderung

  • Novartis Pharma AG
  • Novartis

Zitieren

APA

Jin, M., Douglass, J. A., Elborn, J. S., Agarwal, R., Calhoun, W. J., Lazarewicz, S., Jaumont, X., & Yan, M. (2023). Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice, 11(3), 896-905. https://doi.org/10.1016/j.jaip.2022.12.012

Vancouver

Jin M, Douglass JA, Elborn JS, Agarwal R, Calhoun WJ, Lazarewicz S, et al. Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(3):896-905. doi:10.1016/j.jaip.2022.12.012

BibTeX
@article{Jin2023,
  author = {Jin, Meiling and Douglass, Jo A and Elborn, J Stuart and Agarwal, Ritesh and Calhoun, William J and Lazarewicz, Slawomir and Jaumont, Xavier and Yan, Meng},
  title = {Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2023},
  volume = {11},
  number = {3},
  pages = {896--905},
  doi = {10.1016/j.jaip.2022.12.012}
}
Kostenlos starten →